» Articles » PMID: 36761159

Novel Pre-clinical Mouse Models for Chronic Graft-versus-Host Disease

Overview
Journal Front Immunol
Date 2023 Feb 10
PMID 36761159
Authors
Affiliations
Soon will be listed here.
Abstract

Despite considerable progress in allogeneic hematopoietic cell transplantation (allo-HCT) has been achieved over the past years, chronic Graft-versus-Host Disease (cGvHD) still contributes to high morbidity rates, thus remaining a major hurdle in allo-HCT patients. To understand the complex pathophysiology of cGvHD and to develop refined prophylaxis and treatment strategies, improved pre-clinical models are needed. In this study, we developed two murine cGvHD models, which display high long-term morbidity but low mortality and depict the heterogeneous clinical manifestations of cGvHD seen in patients. We established a haploidentical C57BL/6→B6D2F1 allo-HCT model that uses myeloablative radiation and G-CSF-mobilized splenocytes as stem cell source and a sub-lethally irradiated Xenograft model, which utilizes the transfer of human peripheral blood mononuclear cells (PBMCs) into NOD scid gamma (NSG)-recipients. We characterized both mouse models to exhibit diverse clinical and histopathological signs of human cGvHD as extensive tissue damage, fibrosis/sclerosis, inflammation and B cell infiltration in cGvHD target organs skin, liver, lung and colon and found a decelerated immune cell reconstitution in the late phase after HCT. Our pre-clinical models can help to gain a deeper understanding of the target structures and mechanisms of cGvHD pathology and may enable a more reliable translation of experimental findings into the human setting of allo-HCT.

Citing Articles

Unwanted disorders and xenogeneic graft-versus-host disease in experimental immunodeficient mice: How to evaluate and how to report.

Monzavi S, Muhammadnejad S, Mansouri V, Ashraf H, Ahmadbeigi N Animal Model Exp Med. 2024; 8(1):20-29.

PMID: 39601130 PMC: 11798742. DOI: 10.1002/ame2.12509.

References
1.
Sadeghi B, Aghdami N, Hassan Z, Forouzanfar M, Rozell B, Abedi-Valugerdi M . GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant. 2008; 42(12):807-18. DOI: 10.1038/bmt.2008.261. View

2.
Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

3.
Kong X, Zeng D, Wu X, Wang B, Yang S, Song Q . Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity. J Clin Invest. 2020; 131(1). PMC: 7773409. DOI: 10.1172/JCI135468. View

4.
Hurst J, West R . Taming anxiety in laboratory mice. Nat Methods. 2010; 7(10):825-6. DOI: 10.1038/nmeth.1500. View

5.
Wynn T . Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004; 4(8):583-94. PMC: 2702150. DOI: 10.1038/nri1412. View